The latest study from the University of Pennsylvania School of Medicine found that semaglutide does not increase the risk of depressive symptoms or suicidal thoughts in healthy patients.
Data from over 3,500 participants in four pivotal clinical trials revealed no significant rise in psychiatric issues with semaglutide, reinforcing its safety for weight management.
The findings suggest semaglutide, widely acknowledged for effective weight loss, presents no additional mental health risks for patients without prior major disorders.
Sponsored by Novo Nordisk, the study reinforces the efficacy of semaglutide, emphasizing its beneficial role in managing obesity without the fear of mental health decline.
Collection
[
|
...
]